28 Jul 2021 Bone Therapeutics agrees final settlement with the FSMA regarding clinical studies communication issues in 2016 and 2017 Member news
15 Jul 2021 Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study Member news
15 Jul 2021 Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation Member news
01 Jul 2021 Sequana Medical announces positive results from second interim analysis of North American pivotal alfapump® study (POSEIDON) Member news
14 Jun 2021 Precigen ActoBio announces positive topline results from Phase 1b/2a Study of AG019 ActoBiotics™ Member news
19 May 2021 Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting Member news
11 May 2021 Sequana Medical announces strong top-line results from RED DESERT alfapump DSR® study and expansion of DSR® development programme Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
